UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Raises Holdings in Theravance Biopharma, Inc. (NASDAQ:TBPH)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) by 27.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 150,039 shares of the biopharmaceutical company's stock after buying an additional 32,534 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 0.31% of Theravance Biopharma worth $1,412,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of TBPH. SG Americas Securities LLC lifted its position in shares of Theravance Biopharma by 21.1% during the fourth quarter. SG Americas Securities LLC now owns 19,202 shares of the biopharmaceutical company's stock worth $181,000 after purchasing an additional 3,349 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its position in shares of Theravance Biopharma by 0.7% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 293,936 shares of the biopharmaceutical company's stock worth $2,766,000 after purchasing an additional 2,060 shares during the last quarter. Teacher Retirement System of Texas bought a new stake in shares of Theravance Biopharma during the fourth quarter worth $103,000. Magnetar Financial LLC lifted its position in shares of Theravance Biopharma by 125.8% during the fourth quarter. Magnetar Financial LLC now owns 27,511 shares of the biopharmaceutical company's stock worth $259,000 after purchasing an additional 15,328 shares during the last quarter. Finally, American Century Companies Inc. lifted its position in shares of Theravance Biopharma by 11.9% during the fourth quarter. American Century Companies Inc. now owns 77,931 shares of the biopharmaceutical company's stock worth $733,000 after purchasing an additional 8,289 shares during the last quarter. 99.10% of the stock is currently owned by institutional investors.

Insider Transactions at Theravance Biopharma

In other news, SVP Rhonda Farnum sold 24,000 shares of the business's stock in a transaction dated Monday, June 2nd. The stock was sold at an average price of $11.00, for a total transaction of $264,000.00. Following the sale, the senior vice president now owns 336,918 shares in the company, valued at approximately $3,706,098. The trade was a 6.65% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 6.90% of the company's stock.

Analyst Ratings Changes

Several research firms have recently weighed in on TBPH. HC Wainwright reiterated a "buy" rating and set a $15.00 target price on shares of Theravance Biopharma in a research report on Tuesday, February 25th. Wall Street Zen upgraded Theravance Biopharma from a "hold" rating to a "buy" rating in a report on Wednesday, May 14th. Three analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to data from MarketBeat.com, Theravance Biopharma presently has an average rating of "Hold" and a consensus target price of $11.33.

Theravance Biopharma Stock Down 1.1%

Shares of TBPH stock traded down $0.12 on Wednesday, hitting $10.61. The stock had a trading volume of 272,170 shares, compared to its average volume of 276,146. The business has a 50 day moving average price of $9.43 and a 200 day moving average price of $9.41. The company has a market cap of $530.51 million, a PE ratio of -10.50 and a beta of -0.09. Theravance Biopharma, Inc. has a one year low of $7.44 and a one year high of $11.82.

Theravance Biopharma (NASDAQ:TBPH - Get Free Report) last posted its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.16). Theravance Biopharma had a negative net margin of 78.18% and a negative return on equity of 24.79%. The company had revenue of $15.39 million during the quarter, compared to analysts' expectations of $28.08 million. Equities research analysts expect that Theravance Biopharma, Inc. will post -1.09 EPS for the current year.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.